Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis

Biochemistry

Volumn 45, Issue 47, 2006, Pages 13947-13953

  Argyrou, Argyrides ^a,b   Jin, Lianji ^a   Siconilfi Baez, Linda ^a   Angeletti, Ruth H ^a   Blanchard, John S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; DRUG PRODUCTS; ENZYME KINETICS; METABOLISM; POTASSIUM; PROTONS;

MYCOBACTERIUM TUBERCULOSIS; NANOMOLAR AFFINITY; PYRIDINE NUCLEOTIDE COENZYMES; SOLID SUPPORTS;

BIOMEDICAL ENGINEERING;

ACYL CARRIER PROTEIN; ARGININE; DIHYDROFOLATE REDUCTASE; ISONIAZID; OXIDOREDUCTASE; PROTEOME; PYRIDINE NUCLEOTIDE; PYRIMIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIBOFLAVIN; S ADENOSYLMETHIONINE; VALINE;

AFFINITY CHROMATOGRAPHY; AMINO ACID METABOLISM; ARTICLE; BINDING AFFINITY; BIOSYNTHESIS; CATABOLISM; DRUG TARGETING; LIPID METABOLISM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ISOLATION; PROTON TRANSPORT; STRESS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PROTEOME;

MYCOBACTERIUM TUBERCULOSIS;

EID: 33751583815     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi061874m     Document Type: Article

References (55)

1. Bernstein, J., Lott, W. A., Steinberg, B. A., and Yale, H. L. (1952) Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds, Am. Rev. Tuberc. 65, 357-364.
2. Youatt, J. (1969) A review of the action of isoniazid, Am. Rev. Respir. Dis. 99, 729-749.
3. Bloom, B. R., and Murray, C. J. (1992) Tuberculosis: Commentary on a reemergent killer, Science 257, 1055-1064.
4. Zhang, Y., Heym, B., Allen, B., Young, D., and Cole, S. (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis, Nature 358, 591-593.
5. Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., and Jacobs, W. R., Jr. (1994) InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis, Science 263, 227-230.
6. Nguyen, M., Claparols, C., Bernadou, J., and Meunier, B. (2001) A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts, ChemBioChem 2, 877-883.
7. Rawat, R., Whitty, A., and Tonge, P. J. (2003) The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance, Proc. Natl. Acad. Sci. U.S.A. 100, 13881-13886.
8. Rozwarski, D. A., Grant, G. A., Barton, D. H., Jacobs, W. R., Jr., and Sacchettini, J. C. (1998) Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis, Science 279, 98-102.
9. White, S. W., Zheng, J., Zhang, Y. M., and Rock, C. O. (2004) The structural biology of type II fatty acid biosynthesis, Annu. Rev. Biochem. 791-831.
10. Vilcheze, C., Morbidoni, H. R., Weisbrod, T. R., Iwamoto, H., Kuo, M., Sacchettini, J. C., and Jacobs, W. R., Jr. (2000) Inactivation of the InhA-encoded fatty acid synthase II (FAS II) enoyl-acyl carrier protein reductase induces accumulation of the FAS I end products and cell lysis of Mycobacterium smegmatis, J. Bacteriol. 182, 4059-4067.
11. Barry, C. E., III, Lee, R. E., Mdluli, K., Sampson, A. E., Schroeder, B. G., Slayden, R. A., and Yuan, Y. (1998) Mycolic acids: Structure, biosynthesis and physiological functions, Prog. Lipid Res. 37, 143-179.
12. Takayama, K., Wang, C., and Besra, G. S. (2005) Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis, Clin. Microbiol. Rev. 18, 81-101.
13. Argyrou, A., Vetting, M. W., Aladegbami, B., and Blanchard, J. S. (2006) Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid, Nat. Struct. Mol. Biol. 13, 408-413.
14. Miller, G. P., and Benkovic, S. J. (1998) Stretching exercises: Flexibility in dihydrofolate reductase catalysis, Chem. Biol. 5, R105-R113.
15. Zhang, Y., Vilcheze, C., and Jacobs, W. R., Jr. (2005) in Tuberculosis and the Tubercle Bacillus (Cole, S. T., Eisenach, K. D., McMurray, D. N., and Jacobs, W. R., Jr., Eds.) pp 115-140, ASM Press, Washington, DC.
16. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., III, Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Krogh, A., McLean, J., Moule, S., Murphy, L., Oliver, K., Osborne, J., Quail, M. A., Rajandream, M. A., Rogers, J., Rutter, S., Seeger, K., Skelton, J., Squares, R., Squares, S., Sulston, J. E., Taylor, K., Whitehead, S., and Barrell, B. G. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence, Nature 393, 537-544.
17. Miesel, L., Weisbrod, T. R., Marcinkeviciene, J. A., Bittman, R., and Jacobs, W. R., Jr. (1998) NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis, J. Bacteriol. 180, 2459-2467.
18. + ratio mediates coresistance to isoniazid and ethionamide in mycobacteria, Antimicrob. Agents Chemother. 49, 708-720.
19. Pasca, M. R., Guglierame, P., De Rossi, E., Zara, F., and Riccardi, G. (2005) mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis, Antimicrob. Agents Chemother. 49, 4775-4777.
20. Alland, D., Kramnik, I., Weisbrod, T. R., Otsubo, L., Cerny, R., Miller, L. P., Jacobs, W. R., Jr., and Bloom, B. R. (1998) Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): The effect of isoniazid on gene expression in Mycobacterium tuberculosis, Proc. Natl. Acad. Sci. U.S.A. 95, 13227-13232.
21. Wilson, M., DeRisi, J., Kristensen, H. H., Imboden, P., Rane, S., Brown, P. O., and Schoolnik, G. K. (1999) Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization, Proc. Natl. Acad. Sci. U.S.A. 96, 12833-12838.
22. Betts, J. C., McLaren, A., Lennon, M. G., Kelly, F. M., Lukey, P. T., Blakemore, S. J., and Duncan, K. (2003) Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis, Antimicrob. Agents Chemother. 47, 2903-2913.
23. Boshoff, H. I., Myers, T. G., Copp, B. R., McNeil, M. R., Wilson, M. A., and Barry, C. E., III (2004) The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: Novel insights into drug mechanisms of action, J. Biol. Chem. 279, 40174-40184.
24. Waddell, S. J., Stabler, R. A., Laing, K., Kremer, L., Reynolds, R. C., and Besra, G. S. (2004) The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds, Tuberculosis 84, 263-274.
25. Hughes, M. A., Silva, J. C., Geromanos, S. J., and Townsend, C. A. (2006) Quantitative proteomic analysis of drug-induced changes in mycobacteria, J. Proteome Res. 5, 54-63.
26. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid, Anal. Biochem. 150, 76-85.
27. Ducasse-Cabanot, S., Cohen-Gonsaud, M., Marrakchi, H., Nguyen, M., Zerbib, D., Bernadou, J., Daffe, M., Labesse, G., and Quemard, A. (2004) In vitro inhibition of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein reductase MabA by isoniazid, Antimicrob. Agents Chemother. 48, 242-249.
28. Lei, B., Wei, C. J., and Tu, S. C. (2000) Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor, J. Biol. Chem. 275, 2520-2526.
29. Oda, Y., Owa, T., Sato, T., Boucher, B., Daniels, S., Yamanaka, H., Shinohara, Y., Yokoi, A., Kuromitsu, J., and Nagasu, T. (2003) Quantitative chemical proteomics for identifying candidate drug targets, Anal. Chem. 75, 2159-2165.
30. Mdluli, K., Slayden, R. A., Zhu, Y., Ramaswamy, S., Pan, X., Mead, D., Crane, D. D., Musser, J. M., and Barry, C. E., III (1998) Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid, Science 280, 1607-1610.
31. Palmer, J. L., and Abeles, R. H. (1979) The mechanism of action of S-adenosylhomocysteinase, J. Biol. Chem. 254, 1217-1226.
32. Kloor, D., and Osswald, H. (2004) S-Adenosylhomocysteine hydrolase as a target for intracellular adenosine action, Trends Pharmacol. Sci. 25, 294-297.
33. Stepkowski, T., Brzezinski, K., Legocki, A. B., Jaskolski, M., and Bena, G. (2005) Bayesian phylogenetic analysis reveals two-domain topology of S-adenosylhomocysteine hydrolase protein sequences, Mol. Phylogenet. Evol. 34, 15-28.
34. +-binding proteins in mycobacterial INH resistance, Infect. Immun. 66, 5099-5106.
35. Wierenga, R. K., Terpstra, P., and Hol, W. G. (1986) Prediction of the occurrence of the ADP-binding βαβ-fold in proteins, using an amino acid sequence fingerprint, J. Mol. Biol. 187, 101-107.
36. Kvint, K., Nachin, L., Diez, A., and Nystrom, T. (2003) The bacterial universal stress protein: Function and regulation, Curr. Opin. Microbiol. 6, 140-145.
37. Boon, C., Li, R., Qi, R., and Dick, T. (2001) Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model, J. Bacteriol. 183, 2672-2676.
38. Rosenkrands, I., Slayden, R. A., Crawford, J., Aagaard, C., Barry, C. E., III, and Andersen, P. (2002) Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins, J. Bacteriol. 184, 3485-3491.
39. Florczyk, M. A., McCue, L. A., Stack, R. F., Hauer, C. R., and McDonough, K. A. (2001) Identification and characterization of mycobacterial proteins differentially expressed under standing and shaking culture conditions, including Rv2623 from a novel class of putative ATP-binding proteins, Infect. Immun. 69, 5777-5785.
40. Monahan, I. M., Betts, J., Banerjee, D. K., and Butcher, P. D. (2001) Differential expression of mycobacterial proteins following phagocytosis by macrophages, Microbiology 147, 459-471.
41. Shi, L., Jung, Y. J., Tyagi, S., Gennaro, M. L., and North, R. J. (2003) Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence, Proc. Natl. Acad. Sci. U.S.A. 100, 241-246.
42. Hingley-Wilson, S. M., Sambandamurthy, V. K., and Jacobs, W. R., Jr. (2003) Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis, Nat. Immunol. 4, 949-955.
43. Basso, L. A., Zheng, R., Musser, J. M., Jacobs, W. R., Jr., and Blanchard, J. S. (1998) Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: Enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates, J. Infect. Dis. 178, 769-775.
44. Musser, J. M. (1995) Antimicrobial agent resistance in mycobacteria: Molecular genetic insights, Clin. Microbiol. Rev. 8, 496-514.
45. Winder, F. G., and Collins, P. B. (1970) Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis, J. Gen. Microbiol. 63, 41-48.
46. Takayama, K., Wang, L., and David, H. L. (1972) Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis, Antimicrob. Agents Chemother. 2, 29-35.
47. Quemard, A., Lacave, C., and Laneelle, G. (1991) Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum, Antimicrob. Agents Chemother. 35, 1035-1039.
48. Gangadharam, P. R., Harold, F. M., and Schaefer, W. B. (1963) Selective inhibition of nucleic acid synthesis in Mycobacterium tuberculosis by isoniazid, Nature 198, 712-714.
49. Sassetti, C. M., Boyd, D. H., and Rubin, E. J. (2003) Genes required for mycobacterial growth defined by high density mutagenesis, Mol. Microbiol. 48, 77-84.
50. DeBarber, A. E., Mdluli, K., Bosman, M., Bekker, L. G., and Barry, C. E., III (2000) Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis, Proc. Natl. Acad. Sci. U.S.A. 97, 9677-9682.
51. Baulard, A. R., Betts, J. C., Engohang-Ndong, J., Quan, S., McAdam, R. A., Brennan, P. J., Locht, C., and Besra, G. S. (2000) Activation of the pro-drug ethionamide is regulated in mycobacteria, J. Biol. Chem. 275, 28326-28331.
52. Scorpio, A., and Zhang, Y. (1996) Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus, Nat. Med. 2, 662-667.
53. Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., Kreiswirth, B. N., Barry, C. E., and Baker, W. R. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis, Nature 405, 962-966.
54. Barry, C. E., III, Boshoff, H. I., and Dowd, C. S. (2004) Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis, Curr. Pharm. Des. 10, 3239-3262.
55. Suling, W. J., Reynolds, R. C., Barrow, E. W., Wilson, L. N., Piper, J. R., and Barrow, W. W. (1998) Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase, J. Antimicrob. Chemother. 42, 811-815.